Abstract Number: 1245 • ACR Convergence 2024
Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
Background/Purpose: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain when left untreated. Allopurinol is…Abstract Number: 2012 • ACR Convergence 2024
Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Background/Purpose: Pegloticase, infused every 2 weeks over ≥2 hrs, lowers serum urate (SU) in patients with refractory gout. Decreasing infusion time is expected to improve…Abstract Number: 2559 • ACR Convergence 2024
Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis
Background/Purpose: The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. The aim of…Abstract Number: 0142 • ACR Convergence 2024
The Impact of Hospital Region on Mortality and Other Outcomes in Patients with Gout: A Two-Year Nationwide Analysis
Background/Purpose: Gout is characterized by chronic inflammatory arthritis caused by the deposition of monosodium urate crystals and leads to increased risk of complications, such as…Abstract Number: 0283 • ACR Convergence 2024
Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
Background/Purpose: Patients receiving colchicine for prophylaxis of gout flares are at risk for dose-related gastrointestinal toxicity (nausea, vomiting, diarrhea, abdominal pain) if they have pre-existing…Abstract Number: 1088 • ACR Convergence 2024
Prospective Evaluation of Carotid Atherosclerosis, Urate Deposits and Inflammation After One Year of Treatment in Newly Diagnosed Gout
Background/Purpose: Carotid atherosclerosis is prevalent in patients with gout. A prior cross-sectional study at our hospital demonstrated an association between tophi and positive Power Doppler…Abstract Number: 1289 • ACR Convergence 2024
Gout Education for Primary Care Providers: A Scoping Review
Background/Purpose: Gout is the most common inflammatory arthritis. Despite widespread availability of effective therapies and management guidelines from ACR and EULAR, many gout patients remain…Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…Abstract Number: 2560 • ACR Convergence 2024
Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study
Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…Abstract Number: L15 • ACR Convergence 2023
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Background/Purpose: AR882 is a novel and selective URAT1 inhibitor currently in clinical stage development for the treatment of gout and tophaceous gout and has demonstrated…Abstract Number: 0243 • ACR Convergence 2023
Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center
Background/Purpose: Gout has been associated with high rates of morbidity and mortality in kidney transplant (KT) patients with increased bone destruction and associated cardiovascular and…Abstract Number: 1008 • ACR Convergence 2023
Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use
Background/Purpose: Emergency departments (ED) become a location for non-urgent care when ambulatory care systems are not sufficient. We aim to describe contributing factors to the…Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…Abstract Number: 0244 • ACR Convergence 2023
Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
Background/Purpose: AR882 is a novel, potent, and selective URAT1inhibitor in development for the treatment of gout and tophaceous gout. AR882-202 was a global, multi-center, randomized,…Abstract Number: 1012 • ACR Convergence 2023
Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 45
- Next Page »